Revenue: As of FY2025 Q1, the actual value is USD 2.38 M, missing the estimate of USD 2.596 M.EPS: As of FY2025 Q1, the actual value is USD -1.25.<h3>Segment Revenue</h3><ul><li>Revenues, net: $2,380 thousand for the three months ended March 31, 2025, compared to $2,086 thousand for the same period in 2024, representing a 14% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $10,616 thousand for the three months ended March 31, 2025, compared to - $11,876 thousand for the same period in 2024, representing an 11% decrease.</li><li>Research and Development Expenses: $8,539 thousand for the three months ended March 31, 2025, compared to $9,617 thousand for the same period in 2024, representing an 11% decrease.</li><li>General and Administrative Expenses: $3,984 thousand for the three months ended March 31, 2025, compared to $4,891 thousand for the same period in 2024, representing a 19% decrease.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $7,252 thousand for the three months ended March 31, 2025, compared to - $13,232 thousand for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $7,537 thousand for the three months ended March 31, 2025, compared to - $2,406 thousand used in the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on the development of emavusertib, with ongoing clinical trials in various stages. The company plans to seek additional funding through private or public equity financings, collaborations, or other strategic transactions to support its operations and development programs.</li><li>Non-Core Business: The company may engage in strategic alternatives, such as partnerships, licensing, or sale of assets, but there is no assurance of entering into such transactions on favorable terms.</li></ul>

Curis | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 2.38 M